Uncategorized
EMA accepts application for Oxervate for treatment of neurotrophic keratitis
A registration application for Oxervate eye drops for the treatment of moderate and severe neurotrophic keratitis in adults has been accepted by the European Medicines Agency, according to a Dompé press release.The acceptance allows Oxervate, which was designated as an orphan drug by the EMA’s committee for Orphan Medicinal Products in 2015, to begin a scientific review procedure for marketing authorization, the release said.